Sanofi-Aventis (SNY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Sanofi-Aventis (SNY)

43.36

-0.43 (0.98%)

as of Jul 23, 2026, 8:00:00 pm Market Open.

91 watching

Investor Insights

Jul 23, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Sanofi-Aventis (SNY) has received mixed reviews from experts, with one indicating it as a top pick as of June 5, 2025, while also noting a significant decline of 6.5%. The stock recently triggered its stop-loss at $47, which suggests caution for investors as the market conditions may not be favorable for further investment at this moment. The recommendation from the Stockchase Research Editor, Michael O'Reilly, emphasizes the importance of discipline in trading, suggesting that investors should consider covering their positions. This indicates that while the stock may have been a good pick previously, current market trends are not aligning positively for this investment. Overall, the sentiment appears to be leaning towards a defensive strategy as the situation evolves.

Consensus

Sell

Valuation

Overvalued

Similar

Roche, ROG

BUY

Many of the health care stocks have started to recover or they are not down as much as the market this year. 4% yield and decent growth over time.

Wealthica Track your Stocks in your Watch List

BUY

Had as a toe-hold in the pharmaceutical group that has been out of favour for 3 years, but with only medium success. Facing competition from the generics. Has a great portfolio of drugs and has pretty steady growth.

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

Showing 46 to 48 of 48 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

John Stephenson

Stephenson & Company Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Sanofi-Aventis (SNY)